Pharmaceutical Contract Development & Manufacturing Organization Market Growth Opportunity, 2026-2034

Pharmaceutical Contract Development & Manufacturing Organization Market Growth Opportunity, 2026-2034

REPORT DETAILS

Report Code: PM6512
Base Year: 2025
No. of Pages: 150
Historical Data: 2021-2024
Format: PDF
Published Date:
BUY NOW

Pharmaceutical Contract Development & Manufacturing Organization Market Summary

The global pharmaceutical contract development & manufacturing organization market size was valued at USD 256.90 billion in 2025, growing at a CAGR of 6.49% from 2026 to 2034. Rising R&D expenditure to expand product pipelines along with increasing burden of chronic diseases is propelling the market growth.

Market Statistics

2026 Market Estimate USD 273.22 Billion
2034 Projected Market Size USD 451.80 Billion
CAGR (2026 - 2034) 6.49%
Largest Market in 2025 North America

Key Takeaways

  • North America accounted for 34.60% of the pharmaceutical CDMO market revenue in 2025. Strong pharmaceutical and biotechnology industry presence supported regional dominance.
  • Asia Pacific is projected to grow at a CAGR of 7.18% during the forecast period. CDMO expansion in China and India is supporting regional growth.
  • The small molecule segment accounted for 64.20% of the market revenue in 2025. Extensive use in generic drugs and oral formulations supported its leading position.
  • The drug product segment is projected to grow at a CAGR of 7.12% during the forecast period. Rising demand for formulation development, packaging, and finishing services is supporting segment growth.
  • Contract manufacturing accounted for 66.40% of the service segment revenue in 2025. Increasing outsourcing to reduce costs and meet regulatory requirements supported its dominance.
  • The commercial segment accounted for 68.75% of the workflow segment revenue in 2025. Demand for large-scale drug production among established pharmaceutical companies supported segment leadership.

Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.

What Is a Pharmaceutical CDMO?

A pharmaceutical contract development and manufacturing organization (CDMO) is a specialized company that provides drug development, formulation, and manufacturing services to pharmaceutical and biotechnology companies. It helps drugmakers develop and produce medicines without investing heavily in their own manufacturing facilities, equipment, and technical resources.

Pharmaceutical CDMOs offer services such as active pharmaceutical ingredient (API) manufacturing, formulation development, analytical testing, clinical trial material production, commercial manufacturing, sterile fill-finish, packaging, labeling, and regulatory support. These services cover multiple stages of drug development, from early formulation and drug delivery to large-scale commercial production.

CDMOs support the manufacturing of small molecule drugs, biologics, biosimilars, and advanced therapies. For example, a biotechnology company developing a monoclonal antibody may partner with a CDMO to scale up production, manufacture clinical trial batches, and prepare for commercial supply without building its own specialized facility.

In May 2025, Lonza introduced its Design2Optimize platform to support small molecule API process development and optimization. This example highlights how CDMOs are adopting advanced technologies to improve manufacturing efficiency and process flexibilit (Source: lonza.com).

CDMOs are particularly valuable for small and medium-sized pharmaceutical companies that lack dedicated manufacturing infrastructure. Large pharmaceutical companies also partner with CDMOs to expand production capacity, manage complex manufacturing requirements, and improve supply chain flexibility.

How Does a Pharmaceutical CDMO Work?

A pharmaceutical contract development and manufacturing organization (CDMO) follows a structured process to develop and manufacture medicines. The process involves seven key steps, from partner selection to commercial manufacturing.

  • Partner Selection: Pharmaceutical companies select a CDMO based on its technical expertise, pharmaceutical CDMO services, and manufacturing capabilities. They also assess regulatory compliance, costs, and production capacity.
  • Project Assessment: The CDMO reviews the drug candidate, development goals, and production requirements. This helps establish project timelines, costs, and manufacturing plans.
  • Drug Development: The CDMO supports formulation development, analytical testing, and process optimization. These activities help prepare the drug for safe and efficient manufacturing.
  • Process Validation: The CDMO tests manufacturing processes to ensure consistent product quality and safety. This step also helps meet pharmaceutical manufacturing standards and regulatory requirements.
  • Clinical Manufacturing: The CDMO produces small batches of drugs for clinical trials. These batches undergo quality testing to ensure they meet the required specifications.
  • Regulatory Compliance: The CDMO follows applicable regulatory guidelines and maintains the required documentation. This supports quality assurance and helps pharmaceutical companies prepare for regulatory review.
  • Commercial Manufacturing: After the necessary approvals, the CDMO scales up production to meet market demand. Services may include API manufacturing, finished drug production, packaging, and labeling.

Pharmaceutical Contract Development & Manufacturing Organization Market size 2021 to 2034, reaching USD 451.80 billion at a 6.49% CAGR.

Market Dynamics

Market Driver – Rising R&D Expenditure to Expand Product Pipelines

Pharmaceutical companies are increasing research and development (R&D) spending to develop new drugs and expand product pipelines. This creates demand for CDMOs that support formulation development, analytical testing, and manufacturing scale-up. Outsourcing also helps drugmakers manage complex development needs without building additional facilities. In 2025, Merck reported R&D expenses of USD 15.8 billion, including investment in discovery research and early drug development. This highlights the continued importance of R&D in pharmaceutical innovation (Source: merck.com).

Market Driver- Increasing Burden of Chronic Diseases

The growing burden of chronic diseases is increasing the need for medicines for cancer, diabetes, cardiovascular conditions, and respiratory disorders. Pharmaceutical companies need reliable manufacturing partners to support drug development and production. CDMOs provide specialized facilities and technical expertise to meet these needs. According to the World Health Organization, noncommunicable diseases account for approximately 74% of deaths worldwide, highlighting the continuing need for effective treatments (Source: who.int).

Market Opportunity- Growth of Pharmaceutical Outsourcing

Pharmaceutical outsourcing creates opportunities for CDMOs to support drugmakers across development and manufacturing. Companies can focus on research and commercialization while using external partners for specialized expertise and flexible production capacity. This approach can also reduce upfront investment in facilities. For example, Lonza reported 21.7% sales growth at constant exchange rates in 2025, reflecting demand across its contract development and manufacturing services (Source: lonza.com).

Market Opportunity- Rising Demand for Biologics Manufacturing

Growing demand for biologics, biosimilars, and complex therapies is creating opportunities for CDMOs with specialized manufacturing capabilities. These products often require advanced equipment, controlled production environments, and strict quality systems. CDMOs investing in these capabilities can support clinical development and commercial supply. For example, Lonza expanded its biologics manufacturing capacity in Visp, Switzerland, with a 20,000-liter facility that began initial good manufacturing practice (GMP) runs in 2025 (Source: pharmamanufacturing.com).

Market Restraint- Cost and Capacity Constraints

Pharmaceutical CDMOs face high costs when building specialized facilities, upgrading equipment, and maintaining regulatory compliance. Limited production capacity or delays in facility expansion can also affect project timelines. Outsourcing reduces the need for pharmaceutical companies to own manufacturing infrastructure, but it increases dependence on partner availability and performance. Companies must carefully assess manufacturing capacity, quality systems, and supply chain reliability before selecting a CDMO.

CDMO vs In-House Pharmaceutical Manufacturing

CDMO and in-house pharmaceutical manufacturing offer different approaches to drug development and production. The right approach depends on a company’s production needs, available resources, drug complexity, and long-term business goals.

A pharmaceutical CDMO provides external expertise, manufacturing facilities, specialized equipment, and regulatory support. Pharmaceutical companies can use CDMO services to reduce the need for large investments in their own manufacturing infrastructure. This approach also provides flexible capacity when production requirements change. It can be useful for small molecule drugs, biologics, clinical batches, and commercial manufacturing.

In-house pharmaceutical manufacturing gives companies direct control over production, quality processes, equipment, and manufacturing schedules. However, companies must invest in facilities, skilled employees, technology, maintenance, and regulatory compliance.

Both models involve different cost, capacity, control, and supply chain considerations. The following comparison highlights the main trade-offs between pharmaceutical CDMO outsourcing and in-house manufacturing.

Decision Factor

CDMO Model

In-House Model

Capital Investment

Uses existing facilities and specialist teams, with costs based on services and production volume.

Requires investment in facilities, equipment, and staff.

Technical Expertise

Provides access to specialized expertise in API manufacturing, biologics, formulation, and fill-finish services.

Requires companies to develop and maintain technical expertise internally.

Time to Market

Can reduce setup time when suitable manufacturing capacity is available.

Facility development, equipment qualification, and staff hiring can extend timelines.

Scalability

Offers flexibility to adjust production volumes based on demand and contract terms.

Production capacity depends on existing facilities and available investment.

Control and Intellectual Property

Requires clear agreements to protect intellectual property, data, and confidential information.

Provides direct control over manufacturing processes and internal data.

Supply Chain Resilience

Access to multiple manufacturing sites can diversify supply, but creates reliance on external partners.

Reduces reliance on external manufacturers but may concentrate production at owned facilities.

Source: Polaris Market Research Analysis

Biologics, Cell and Gene Therapy CDMOs

Biologics CDMOs support the development and manufacturing of complex medicines made from living cells or biological materials. These services include monoclonal antibody manufacturing, cell and gene therapy CDMO services, viral vector manufacturing, and sterile fill-finish. Such processes require specialized facilities, skilled teams, and strict quality controls.

Demand for advanced therapy manufacturing is growing as pharmaceutical companies develop biologics, biosimilars, and gene-based treatments. These medicines often need specific production methods and careful handling. CDMOs help companies develop manufacturing processes, produce clinical trial materials, and scale up production for commercial supply.

Cell and gene therapies also create unique manufacturing challenges. Production may involve living cells, viral vectors, and patient-specific materials. This can make batch consistency, storage, transport, and production scale more difficult to manage. Specialized CDMOs help address these needs through controlled production environments and tailored manufacturing processes.

For example, a biotechnology company developing a gene therapy may partner with a CDMO for viral vector production, process development, and quality testing. This allows the company to access specialized expertise without building its own advanced manufacturing facility. As more complex therapies move through clinical development, CDMOs with suitable technologies and regulatory experience can support their path toward commercialization.

Technology Innovation and Digital Transformation

Technology innovation is changing pharmaceutical CDMO services by improving production efficiency, process control, and product quality. CDMOs are adopting continuous pharmaceutical manufacturing, automation, and digital tools to manage complex production needs. These technologies can help reduce waste, improve consistency, and support faster manufacturing.

Continuous pharmaceutical manufacturing allows materials to move through connected production steps instead of being processed only in separate batches. This approach can improve process control and support consistent output. The U.S. Food and Drug Administration (FDA) issued ICH Q13 guidance in 2023 to explain scientific and regulatory considerations for continuous manufacturing of drug substances and drug products.

Single-use bioprocessing CDMO facilities use disposable components such as bags, tubing, and filters. These systems can reduce cleaning needs and lower the risk of cross-contamination between production runs. They are especially useful in biologics manufacturing, where flexibility and contamination control are important.

AI in pharmaceutical manufacturing can help analyze production data, identify process changes, and support quality monitoring. Automated equipment can also improve process consistency and reduce manual work. Digital quality management CDMO systems help maintain records, track deviations, manage changes, and support audits. However, these tools require proper validation, data protection, and human oversight to ensure reliable results.

Quality, Regulatory Compliance and Supplier Risk

Quality and regulatory compliance are essential for pharmaceutical CDMOs because manufacturing errors can affect product safety and supply. CDMOs must follow good manufacturing practices (GMP), maintain accurate records, and use validated processes. These requirements apply to API manufacturing, finished drug production, biologics, and sterile fill-finish services.

Process validation helps confirm that manufacturing methods can consistently produce medicines that meet approved quality standards. Regular audits, equipment qualification, and staff training also help maintain compliance. Data integrity is equally important. Production records and laboratory results must be accurate, complete, and protected from unauthorized changes. The FDA's guidance on data integrity and drug GMP explains these expectations.

Change control is another important part of CDMO regulatory compliance. Changes to equipment, materials, manufacturing methods, or suppliers must be assessed and documented. Pharmaceutical companies should also review a CDMO's inspection history, quality systems, and subcontracting arrangements before signing a contract.

Biotech supplier risk can increase when production depends on a limited number of suppliers or locations. China CDMO sourcing risk and wider geopolitical uncertainty have also increased attention to supply chain diversification. Companies can reduce disruption risks by assessing critical raw materials, qualifying alternative suppliers, and reviewing backup manufacturing options. Clear quality agreements and regular supplier reviews help protect product quality and supply continuity.

BIOSECURE Act: Implications for Pharmaceutical CDMO Sourcing

The BIOSECURE Act has increased attention to biotechnology supplier risks and pharmaceutical CDMO sourcing in the United States. The relevant provisions were included in the National Defense Authorization Act for Fiscal Year 2026, signed into law in December 2025. They establish restrictions on certain federal government procurement and contracting involving biotechnology companies of concern (Source: visionlifesciences.com).

For pharmaceutical companies, these provisions make supplier ownership, subcontracting, and manufacturing arrangements important parts of risk assessment. Companies that supply products or services under U.S. federal contracts may need to review whether their biotechnology equipment or services fall within the restrictions. The potential impact depends on the contract, applicable effective dates, and relevant designation decisions.

The policy also highlights the importance of supply chain diversification. Pharmaceutical companies may review their dependence on specific biotechnology suppliers, including suppliers based in China, and assess alternative manufacturing options. However, the law should not be interpreted as a blanket prohibition on all private-sector business with Chinese CDMOs.

What the Law Does and Does Not Mean

The BIOSECURE Act provisions restrict certain federal procurement and contracting activities involving biotechnology companies of concern. They can also affect contractors that use covered equipment or services in performing relevant federal contracts, subject to the law's scope and implementation.

The provisions do not automatically prohibit every pharmaceutical company from working with every Chinese CDMO. Buyers should verify applicable designations, contract requirements, effective dates, and exceptions before making sourcing decisions. Legal counsel can help assess how the restrictions apply to specific arrangements.

Questions Buyers Should Ask CDMO Partners

Pharmaceutical companies should ask CDMO partners about ownership, relevant designations, subcontractors, and the origin of critical biotechnology equipment and services. They should also understand who can access manufacturing data and how sensitive information is protected.

Buyers should review backup manufacturing sites, alternative suppliers, and continuity plans for critical products. They should ask whether existing contracts could be affected by new restrictions and how the CDMO manages regulatory changes. Legal counsel should review relevant federal contract obligations and sourcing risks before major manufacturing or supply agreements are finalized.

Pharmaceutical Contract Development & Manufacturing Organization Market trends, growth drivers and leading industry players.

Pharmaceutical CDMO Market Segmentation

By Type Analysis

The global pharmaceutical contract development and manufacturing organization (CDMO) market segmentation, based on type, includes small molecules and large molecules. The small molecule segment accounted for 64.20% of market revenue in 2025. Its leading position is supported by the widespread use of small molecule drugs in generic medicines and oral formulations. Pharmaceutical companies rely on CDMO services for active pharmaceutical ingredient (API) manufacturing, formulation development, and large-scale drug production.

The large molecule segment is expected to grow at a CAGR of 7.47% during 2026–2034. Growth is supported by increasing demand for biologics, biosimilars, monoclonal antibodies, and cell and gene therapies. These complex medicines require specialized facilities, advanced manufacturing technologies, and strict quality controls. Pharmaceutical companies are partnering with biologics CDMOs to improve production efficiency, expand manufacturing capacity, and support clinical development and commercial supply.

By Product Analysis

The global pharmaceutical contract development and manufacturing organization (CDMO) market segmentation, based on product, includes active pharmaceutical ingredients (API) and drug products. The API segment accounted for 58.40% of market revenue in 2025. Its leading position is supported by pharmaceutical companies outsourcing large-scale API manufacturing to reduce costs, access specialized expertise, and meet quality and regulatory requirements.

The drug product segment is expected to grow at a CAGR of 7.12% during 2026–2034. Growth is driven by rising demand for formulation development, finished dosage manufacturing, packaging, and labeling services. CDMOs support the production of tablets, capsules, and injectable medicines. Integrated CDMO services that combine API production with finished drug manufacturing can also improve coordination across the pharmaceutical supply chain and simplify production planning.

By Service

The global pharmaceutical contract development and manufacturing organization (CDMO) market segmentation, based on service, includes contract development, contract manufacturing, API manufacturing, finished drug product manufacturing, packaging and labeling, regulatory affairs, and others. The contract manufacturing segment accounted for 66.40% of market revenue in 2025. Its leading position is supported by increasing production outsourcing, lower capital investment needs, and demand for compliant manufacturing services.

The contract development segment is expected to grow at a CAGR of 7.18% during 2026–2034. Growth is driven by rising demand for early-stage formulation development, analytical testing, and process optimization. These services help pharmaceutical companies improve drug development processes and prepare products for clinical trials. CDMOs also provide technical expertise that supports efficient development and a smoother transition to commercial manufacturing.

By Workflow

The global pharmaceutical contract development and manufacturing organization (CDMO) market segmentation, based on workflow, includes clinical and commercial manufacturing. The commercial segment accounted for 68.75% of market revenue in 2025. Its leading position is supported by established pharmaceutical companies outsourcing large-scale drug production to meet global demand, improve operational efficiency, and maintain consistent product supply.

The clinical segment is expected to grow at a CAGR of 7.38% during 2026–2034. Growth is driven by increasing clinical trial activity, early-stage drug development, and demand for small-batch manufacturing. Pharmaceutical CDMOs provide clinical trial material production, formulation development, and analytical testing to support drug candidates through clinical studies. These services are particularly valuable for biotechnology startups and smaller pharmaceutical companies with limited manufacturing resources.

By Therapeutic Area

The global pharmaceutical contract development and manufacturing organization (CDMO) market segmentation, based on therapeutic area, includes oncology, infectious diseases, neurological disorders, cardiovascular disease, metabolic disorders, autoimmune diseases, respiratory diseases, ophthalmology, gastrointestinal disorders, orthopedic diseases, dental diseases, and others. The oncology segment accounted for 32.15% of market revenue in 2025. Growth is supported by increasing demand for cancer medicines, targeted therapies, and biologics, which require specialized drug development and manufacturing services.

The infectious diseases segment is expected to grow at a CAGR of 8.16% during 2026–2034. Growth is driven by continued drug development, demand for effective treatments, and the need for reliable manufacturing capacity. Pharmaceutical CDMOs support the development and production of anti-infective medicines through formulation development, API manufacturing, and finished drug production. These services help pharmaceutical companies respond to changing treatment needs and expand medicine supply.

By End Use

The global pharmaceutical contract development and manufacturing organization (CDMO) market segmentation, based on end use, includes small, medium, and large pharmaceutical companies. The large pharmaceutical companies segment accounted for 68.40% of market revenue in 2025. Its leading position is supported by increasing reliance on CDMOs to expand production capacity, improve efficiency, and accelerate the time-to-market for small and large molecule drugs.

The medium pharmaceutical companies segment is expected to grow at a CAGR of 7.12% during 2026–2034. Growth is driven by increasing demand for specialized manufacturing services, regulatory support, and advanced production technologies. Pharmaceutical CDMOs help medium-sized companies access technical expertise and manufacturing facilities without major infrastructure investments. This allows them to focus on drug development while meeting production and quality requirements.

Pharmaceutical Contract Development & Manufacturing Organization Market share by Services, Contract Development, Contract Manufacturing 2021 to 2034.

Regional Pharmaceutical CDMO Market Insights

The pharmaceutical contract development and manufacturing organization (CDMO) market is expanding across North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. Regional growth is influenced by pharmaceutical manufacturing capacity, drug development activity, regulatory requirements, and demand for outsourcing services. CDMOs support pharmaceutical companies through API manufacturing, formulation development, biologics production, and finished drug manufacturing.

North America Pharmaceutical CDMO Market

North America accounted for the largest share of the global pharmaceutical CDMO market, representing 34.60% of market revenue in 2025. The region benefits from a strong presence of pharmaceutical and biotechnology companies, advanced manufacturing facilities, and established regulatory systems. Growing demand for biologics, sterile fill-finish, and advanced therapies is supporting pharmaceutical CDMO services across the region.

U.S. Pharmaceutical CDMO Market

The U.S. pharmaceutical CDMO market is supported by significant drug development activity and demand for specialized manufacturing services. Pharmaceutical companies partner with CDMOs to improve production capacity, maintain quality standards, and accelerate time-to-market. In June 2025, Thermo Fisher Scientific expanded its collaboration with Sanofi through the acquisition of Sanofi's sterile manufacturing facility in Ridgefield, New Jersey. The expansion strengthened its sterile manufacturing network and supported its end-to-end drug development and manufacturing services (Source: ir.thermofisher.com).

Canada Pharmaceutical CDMO Market

The Canada pharmaceutical CDMO market benefits from pharmaceutical research, biotechnology development, and demand for contract manufacturing services. Companies use CDMOs for formulation development, clinical trial materials, and commercial drug production. Canada's research institutions and biotechnology companies also create opportunities for specialized manufacturing partnerships. Demand for quality-compliant production and access to North American pharmaceutical supply chains can support further market development.

Asia Pacific Pharmaceutical CDMO Market

Asia Pacific is the fastest-growing region in the pharmaceutical CDMO market, with a projected CAGR of 7.18% during 2026–2034. Growth is supported by expanding manufacturing facilities, rising demand for generic medicines and biosimilars, and competitive production costs. Pharmaceutical companies are increasingly outsourcing drug development and manufacturing to regional CDMOs to access specialized expertise and expand production capacity.

China Pharmaceutical CDMO Market

The China pharmaceutical CDMO market is supported by established pharmaceutical manufacturing capabilities, biotechnology research, and demand for contract development services. Local CDMOs provide API manufacturing, biologics production, and finished drug manufacturing. However, international buyers are also assessing supplier concentration, regulatory requirements, and supply chain risks when selecting Chinese manufacturing partners.

Japan Pharmaceutical CDMO Market

The Japan pharmaceutical CDMO market benefits from advanced pharmaceutical research, established quality standards, and demand for specialized drug manufacturing. CDMOs support pharmaceutical companies with formulation development, analytical testing, and commercial production. Growing interest in biologics and complex medicines is creating opportunities for providers with advanced manufacturing capabilities.

India Pharmaceutical CDMO Market

The India pharmaceutical CDMO market is supported by domestic manufacturing capabilities, skilled professionals, and competitive production costs. In August 2024, the Union Cabinet approved the BioE3 Policy to promote biotechnology-based manufacturing and support innovation. The policy aims to strengthen India's biomanufacturing ecosystem and create opportunities for pharmaceutical and biotechnology companies.

Europe Pharmaceutical CDMO Market

Europe holds a significant position in the pharmaceutical CDMO market, supported by established pharmaceutical companies, advanced manufacturing infrastructure, and strict quality standards. Demand for biologics, contract research, and advanced therapy medicinal products (ATMPs) is encouraging CDMOs to expand their service portfolios.

UK Pharmaceutical CDMO Market

The UK pharmaceutical CDMO market benefits from biotechnology research, pharmaceutical innovation, and demand for outsourced drug development. CDMOs support clinical manufacturing, formulation development, and biologics production. Research partnerships and demand for specialized manufacturing services create opportunities for market expansion.

France Pharmaceutical CDMO Market

The France pharmaceutical CDMO market is supported by established pharmaceutical manufacturing, biotechnology research, and demand for contract development services. Companies use CDMOs for drug formulation, manufacturing, and quality assurance. Investments in advanced therapies and biologics are also creating opportunities for specialized service providers.

Latin America Pharmaceutical CDMO Market

The Latin America pharmaceutical CDMO market is supported by rising demand for medicines, domestic pharmaceutical production, and growing interest in manufacturing partnerships. CDMOs can help pharmaceutical companies improve production capacity and access technical expertise. Demand for generic medicines and cost-efficient manufacturing may create further opportunities across the region.

Middle East and Africa Pharmaceutical CDMO Market

The Middle East and Africa pharmaceutical CDMO market is influenced by growing healthcare needs, pharmaceutical manufacturing initiatives, and efforts to strengthen local medicine supply. Partnerships with international CDMOs can help companies access manufacturing expertise and improve production capabilities. Investments in pharmaceutical infrastructure and demand for reliable medicine supply may support regional market development.

Pharmaceutical Contract Development & Manufacturing Organization Market by region, North America leading ahead of Europe and Asia Pacific.

Real-World Pharmaceutical CDMO Use Cases

Pharmaceutical CDMOs support drug development and manufacturing across different stages of the product lifecycle. Their services help companies access specialized facilities, maintain quality standards, and scale production based on demand. The following table highlights common pharmaceutical CDMO use cases and their key requirements.

Use Case

CDMO Services

Key Requirements

Business Benefits

API and Highly Potent API Production

API synthesis, process optimization, and scale-up

Process control, containment, and worker safety

Supports efficient production of complex drug ingredients

Clinical Trial Batch Production

Small-batch manufacturing and analytical testing

Flexible batch sizes, quality testing, and change control

Supports clinical trials and early-stage drug development

Biologics and Sterile Fill-Finish

Biologics manufacturing, sterile filling, and quality testing

Specialized facilities, contamination control, and GMP compliance

Supports safe production of biologics and injectable medicines

Cell and Gene Therapy Manufacturing

Viral vector production, cell processing, and manufacturing support

Cell handling, chain of identity, and chain of custody

Supports advanced therapy development and production

Injectable Formulation and Packaging

Formulation, aseptic filling, labeling, and packaging

Sterility assurance, packaging integrity, and quality checks

Helps maintain product quality and prepare medicines for distribution

Source: Polaris Market Research Analysis

Key Players & Competitive Analysis

The global pharmaceutical contract development & manufacturing organization (CDMO) market is dominated by intense competition and strategic buildup among leading players aimed at providing end-to-end drug development and manufacturing services. Market leaders are making significant investments in biologics manufacturing, innovative formulation technologies, and regulatory-approved infrastructure to cater to rising demand for small- and large-molecule therapies.

Key players operating in the global pharmaceutical contract development and manufacturing organization (CDMO) market include Boehringer Ingelheim, Catalent, FAMAR, FUJIFILM Biotechnologies, Jubilant Pharmova Limited, Lonza, Thermo Fisher Scientific (Patheon), Pfizer CentreOne, Recipharm, Samsung Biologics, Siegfried, Syngene International Limited, WuXi AppTec, Vetter, and Zhejiang Hisun Pharmaceutical Co., Ltd.

Lonza provides pharmaceutical development and manufacturing services across small molecules, biologics, and advanced therapies. Its capabilities support drug development, process optimization, and commercial-scale production for pharmaceutical and biotechnology companies.

Catalent offers drug development, clinical supply, biologics manufacturing, and sterile fill-finish services. Following its acquisition by Novo Holdings in December 2024, Catalent continues to support pharmaceutical companies with development and commercial manufacturing solutions (Source: catalent.com).

Key Players

  • Boehringer Ingelheim
  • Catalent
  • FAMAR
  • FUJIFILM Biotechnologies
  • Jubilant Pharmova Limited
  • Lonza
  • Thermo Fisher Scientific (Patheon)
  • Pfizer CentreOne
  • Recipharm
  • Samsung Biologics
  • Siegfried
  • Syngene International Limited
  • WuXi AppTec
  • Vetter
  • Zhejiang Hisun Pharmaceutical Co., Ltd.

Vendor Positioning Table

Company / Brand

Headquarters

Key Service Capabilities

Main Focus

Boehringer Ingelheim

Ingelheim am Rhein, Germany

Biopharmaceutical development and manufacturing

Biologics

Catalent

Somerset, New Jersey, USA

Drug development, clinical supply, and commercial manufacturing

Biologics and pharmaceuticals

FAMAR

Athens, Greece

Formulation and finished dosage manufacturing

Pharmaceutical products

FUJIFILM Biotechnologies

Tokyo, Japan

Biologics development and manufacturing

Biologics

Jubilant Pharmova Limited

Noida, India

API manufacturing, sterile injectables, and contract development

APIs and pharmaceuticals

Lonza

Basel, Switzerland

Small molecule, biologics, and advanced therapy manufacturing

Small molecules and biologics

Thermo Fisher Scientific (Patheon)

Waltham, Massachusetts, USA

Drug development, clinical manufacturing, and commercial production

Pharmaceutical products

Pfizer CentreOne

New York City, New York, USA

API and finished dosage contract manufacturing

Pharmaceutical manufacturing

Recipharm

Stockholm, Sweden

Pharmaceutical development and contract manufacturing

Drug products

Samsung Biologics

Incheon, South Korea

Biologics development and manufacturing

Biologics

Siegfried

Zofingen, Switzerland

Drug substance and drug product development and manufacturing

APIs and finished products

Syngene International Limited

Bengaluru, India

Contract research, drug development, and manufacturing

Research and pharmaceuticals

WuXi AppTec

Shanghai, China

Pharmaceutical research, development, and manufacturing-related services

Drug development

Vetter

Ravensburg, Germany

Sterile injectable manufacturing and fill-finish

Injectable medicines

Zhejiang Hisun Pharmaceutical

Taizhou, Zhejiang, China

API and finished drug manufacturing

Pharmaceutical ingredients and medicines

Source: Polaris Market Research Analysis

Recent Developments

  • August 2026: Piramal Pharma Limited completed the acquisition of a controlling stake in Yapan Bio, making it a subsidiary. The transaction strengthens Piramal Pharma Solutions' biologics CDMO capabilities, including process development, characterization, and GMP manufacturing for vaccines and biologics (Source: ptiprnews)
  • July 2026: Samsung Biologics announced a proposed all-cash acquisition of PolyPeptide Group for approximately CHF 1.46 billion. The transaction aims to expand Samsung Biologics' capabilities into peptide-based APIs and strengthen its manufacturing network across the United States, Europe, and India, subject to completion conditions and regulatory approvals. (Source: samsungbiologics.com)
  • June 2026: Lonza announced plans to expand highly potent API and antibody-drug conjugate (ADC) payload-linker manufacturing capacity at its Visp facility in Switzerland. The investment will strengthen its commercial-scale manufacturing capabilities and support growing demand for complex oncology therapies. (Source: lonza.com)
  • March 2026: Cambrex completed initial engineering studies for a new large-scale active pharmaceutical ingredient (API) manufacturing plant in Charles City, Iowa. The planned USD 120 million expansion is expected to increase large-scale manufacturing capacity by 20% and support complex APIs, highly potent compounds, and commercial-scale peptide manufacturing. (Source: cambrex.com)
  • August 2025: Polpharma Biologics and Fresenius Kabi entered into a global licensing agreement for PB016, a proposed vedolizumab biosimilar. Under the deal, Polpharma oversaw development and manufacturing, while Fresenius Kabi managed global commercialization, excluding the MENA region. (Source: polpharmabiologics.com)
  • April 2025: Thermo Fisher introduced an enhanced CHO K-1 cell line that shortened IND timelines from 13 to nine months, improved protein expression levels, and accelerated biologics development through its integrated CDMO, CRO, and bioprocessing capabilities. (Source: pharmaceuticalmanufacturer.media)

Future Outlook

The pharmaceutical contract development and manufacturing organization (CDMO) market is expected to expand as pharmaceutical companies seek flexible manufacturing solutions and specialized technical expertise. Growing demand for biologics, biosimilars, cell and gene therapies, and complex drug formulations is likely to create new opportunities for pharmaceutical CDMO services.

Advances in continuous manufacturing, automation, and digital quality management may improve production efficiency and product consistency. CDMOs that invest in advanced facilities and regulatory compliance can strengthen their position in global pharmaceutical supply chains. However, high infrastructure costs, capacity limitations, supplier dependence, and changing regulations may create challenges. Supply chain diversification and strategic partnerships are expected to remain important for long-term market growth.

Research Methodology

The pharmaceutical contract development and manufacturing organization (CDMO) market research uses primary and secondary research to assess market trends, industry developments, competitive activity, and growth opportunities. The study examines pharmaceutical outsourcing, drug development activities, manufacturing capabilities, and demand for specialized CDMO services.

Primary research may include interviews and discussions with industry participants, such as pharmaceutical manufacturers, CDMO service providers, industry experts, and other relevant stakeholders. These inputs help provide insights into outsourcing practices, manufacturing requirements, regulatory challenges, and emerging technologies.

Secondary research involves reviewing publicly available information from company websites, annual reports, investor presentations, government publications, regulatory agencies, industry associations, and scientific publications. These sources help assess company developments, manufacturing investments, and broader pharmaceutical industry trends.

Market estimates and forecasts are developed by evaluating available industry data, historical trends, market drivers, restraints, and expected changes in pharmaceutical manufacturing demand. Relevant factors include biologics development, contract manufacturing activity, regulatory requirements, and regional production capacity. Data is reviewed for consistency, and estimates are assessed against available supporting information.

The resulting analysis provides an overview of market size, growth prospects, segmentation, regional trends, and the competitive landscape. Forecasts represent estimates based on the assumptions and information available during the research period and may change as market conditions evolve.

Pharmaceutical Contract Development & Manufacturing Organization Market Segmentation

By Type Outlook (Revenue, USD Billion, 2021–2034)

  • Small Molecule
    • Branded
    • Generic
  • Large Molecule
    • Biologics
    • Biosimilar

By Product Outlook (Revenue, USD Billion, 2021–2034)

  • API
    • Traditional Active Pharmaceutical Ingredient (Traditional API)
    • Highly Potent Active Pharmaceutical Ingredient (HP-API)
    • Biologics
    • Others
  • Drug Product
    • Oral solid dose
    • Semi-solid dose
    • Liquid dose
    • Others

By Services Outlook (Revenue, USD Billion, 2021–2034)

  • Contract Development
  • Contract Manufacturing
  • API Manufacturing
  • Finished Drug Products Manufacturing
  • Packaging and Labelling
  • Regulatory Affairs
  • Others

By Workflow Outlook (Revenue, USD Billion, 2021–2034)

  • Clinical
  • Commercial

By Therapeutic Area Outlook (Revenue, USD Billion, 2021–2034)

  • Oncology
  • Infectious Diseases
  • Neurological Disorders
  • Cardiovascular Disease
  • Metabolic Disorders
  • Autoimmune Diseases
  • Respiratory Diseases
  • Ophthalmology
  • Gastrointestinal Disorders
  • Orthopedic Diseases
  • Dental Diseases
  • Others

By End Use Outlook (Revenue, USD Billion, 2021–2034)

  • Small Pharmaceutical Companies
  • Medium Pharmaceutical Companies
  • Large Pharmaceutical Companies

By Regional Outlook (Revenue, USD Billion, 2021–2034)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Netherlands
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Malaysia
    • South Korea
    • Indonesia
    • Australia
    • Vietnam
    • Rest of Asia Pacific
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Israel
    • South Africa
    • Rest of Middle East & Africa
  • Latin America
    • Mexico
    • Brazil
    • Argentina
    • Rest of Latin America

Pharmaceutical Contract Development & Manufacturing Organization Market Report Scope

Report Attributes

Details

Market Size in 2025

USD 256.90 Billion

Market Size in 2026

USD 273.22 Billion

Revenue Forecast by 2034

USD 451.80 Billion

CAGR

6.49% from 2026 to 2034

Base Year

2025

Historical Data

2021–2024

Forecast Period

2026–2034

Quantitative Units

Revenue in USD Billion and CAGR from 2026 to 2034

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Industry Trends

Segments Covered

  • By Type
  • By Product
  • By Service
  • By Workflow
  • By Therapeutic Area
  • By End Use

Regional Scope

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Competitive Landscape

  • Pharmaceutical Contract Development & Manufacturing Organization Industry Trend Analysis (2025)
  • Company Profiles/Industry participants profiling includes company overview, financial information, product/service benchmarking, and recent developments

Report Format

  • PDF + Excel

Customization

Report customization as per your requirements with respect to countries, regions, and segmentation.

Source: Polaris Market Research Analysis

Pharmaceutical Contract Development & Manufacturing Organization Market FAQ's

A pharmaceutical contract development and manufacturing organization (CDMO) provides drug development, formulation, testing, and manufacturing services to pharmaceutical and biotechnology companies. It supports drug production from early development to commercial manufacturing.

The pharmaceutical CDMO market is driven by increasing drug development activity, rising demand for biologics, and growing outsourcing of manufacturing services. Companies also use CDMOs to access specialized expertise and flexible production capacity.

The pharmaceutical CDMO market is projected to grow at a CAGR of 6.49% during 2026–2034. Growth is expected to be supported by pharmaceutical outsourcing, advanced therapy development, and demand for specialized manufacturing services.

The small molecule segment held the largest share of the pharmaceutical CDMO market in 2025. Its leading position is supported by the widespread use of generic medicines and oral drug formulations.

North America dominated the pharmaceutical CDMO market in 2025. The region benefits from established pharmaceutical companies, advanced manufacturing facilities, and strong demand for outsourced drug development and production.

Asia Pacific is expected to be the fastest-growing region during the forecast period. Expanding manufacturing capacity in China and India, competitive production costs, and rising demand for pharmaceutical outsourcing support regional growth.

Pharmaceutical companies should assess a CDMO's manufacturing capabilities, regulatory compliance, technical expertise, production capacity, and quality systems. They should also consider costs, intellectual property protection, supply chain reliability, and experience with the relevant drug type.

The pharmaceutical CDMO market was valued at USD 256.90 billion in 2025 and is projected to reach USD 451.80 billion by 2034, growing at a 6.49% CAGR.

Page last updated on:

  • Author:

    Shreyas Shirsat

    Senior Research Associate

    As a Senoir Research Associate, Shreyas specializes in both qualitative and quantitative research methodologies. With the academic background of medical biotechnology, Shreyas easily identifies emerging trends in healthcare domains, such as diagnostics, animal health, healthcareIT and medical devices. He emphasizes competitive landscapes, recent technology adoption, and growth opportunities in the markets. Shreyas provides detailed competitive and research analysis that supports CXOs in strategic decision-making.

    Download Sample